Technical and Economical Evaluation of Downstream Processing Options for Monoclonal Antibody (Mab) Production - Updated downstream processes can pave the way for increased productivity, now and in the

ADVERTISEMENT

Technical and Economical Evaluation of Downstream Processing Options for Monoclonal Antibody (Mab) Production
Updated downstream processes can pave the way for increased productivity, now and in the future.


BioPharm International


References

1. Slaff G. Application of Technology Platforms to the Purification of Monoclonal Antibodies; presentation at BioProcess International European Conference, 2005 April 11–14, Berlin, Germany.

2. Grönberg A, Monié E, Murby M, Rodrigo G,Wallby E, Johansson HJ. A strategy for development of a mAb purification platform; poster presentation at BioProcess International European Conference, 2006 February 20–23, Prague, Czech Republic.

3. Wurm F. Production of recombinant protein therapeutics in cultivated mammalian cells. Nature Biotechnol. 2004; 22(11): 1393–1398.

4. Johansson, HJ. Advances in the Purification of Monoclonal Antibody-Based Therapeutics, presented at IBC Life Sciences Conference "Antibody Development & Production," 2006 March 1–3, Carlsbad, CA.

5. Werner R. presentation at 4th Annual Biological Production Forum, 2005 April, Edinburgh, UK.

6. Bezy P. Efficient Pilot Plant Utilization, presented at BioProcess International European Conference, 2005 April 11–14, Berlin, Germany.

7. Ambrosius D. Assessment of Purification Technologies, presented at BioProcess International European Conference, 2005 April 11–14, Berlin, Germany.

8. Ghose S, Hubbard B, Cramer SM. Biotechnol. Prog. 2005; 21: 498–508.

9. Zhou JX, Tressel T. Basic Concepts in Q Membrane Chromatography for Large-Scale Antibody Production, Biotechnol. Prog. 2006; 22: 341–349.

10. Johansson HJ, Lacki K, Brekkan E, Antti M, Bj�an T, Grönberg A. Multi-modal chromatography for purification of monoclonal antibodies, poster presentation at Recovery of Biological Products XII, 2006 April 2–7, Phoenix, AZ.

11. Ghose S, Allen M, Hubbard B, Brooks C, Cramer. SM. Antibody variable region interactions with Protein A: Implications for the Development of Generic Purification Processes. Biotechnol and Bioeng.2005; 92(6): 665–673.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Hospira Issues Recall Due to Mold Contamination
July 11, 2014
Baxter Issues Recall Due to Particulate Matter
July 11, 2014
FDA Publishes Guidance on ANDA Submissions
July 10, 2014
Biotech Industry Forms International Council
July 10, 2014
EMA Recommends 39 Drugs in First Half of 2014
July 10, 2014
Author Guidelines
Source: BioPharm International,
Click here